These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10207893)

  • 1. Antisense therapeutics.
    Persidis A
    Nat Biotechnol; 1999 Apr; 17(4):403-4. PubMed ID: 10207893
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GTI-2040. Lorus Therapeutics.
    Orr RM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthetic oligonucleotides and their application in gene therapy].
    Iribarren AM
    Medicina (B Aires); 1995; 55(3):263-6. PubMed ID: 8544726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Current clinical trials of G3139.
    Tock B; Zwiebel JA; Schoenfeldt M
    Oncology (Williston Park); 2003 Sep; 17(9):1244-6, 1251-3, 1258. PubMed ID: 14569852
    [No Abstract]   [Full Text] [Related]  

  • 11. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long march of antisense.
    Jones D
    Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
    [No Abstract]   [Full Text] [Related]  

  • 13. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antisense oligonucleotides: a new class of biologically active molecules].
    Uteshev DB; Korostelev SA; Sergeev AV; Uteshev BS
    Eksp Klin Farmakol; 2004; 67(3):76-9. PubMed ID: 15341077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense therapeutics: a promise waiting to be fulfilled.
    Phillips MI
    Methods Mol Med; 2005; 106():3-10. PubMed ID: 15375309
    [No Abstract]   [Full Text] [Related]  

  • 16. Antisense and sensibility.
    Dove A
    Nat Biotechnol; 2002 Feb; 20(2):121-4. PubMed ID: 11821852
    [No Abstract]   [Full Text] [Related]  

  • 17. Antisense DNA and RNA agents against picornaviruses.
    Lim T; Yuan J; Zhang HM; Sall A; Liu Z; Su Y; Yang D
    Front Biosci; 2008 May; 13():4707-25. PubMed ID: 18508540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.